[The role of therapeutic drug monitoring--what to study and when?].
Laine
Kari
K
TYKS:n kliinisen farmakologian yksikkö, Turku. kari.laine@utu.fi
D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D001682:Biological Availability; D016903:Drug Monitoring / Q000592:standards* / Q000639:trends; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D007231:Infant, Newborn; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D012680:Sensitivity and Specificity
D000889:Anti-Arrhythmia Agents; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D007166:Immunosuppressive Agents; D004364:Pharmaceutical Preparations